The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve
NCT ID: NCT01129830
Last Updated: 2014-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
EARLY_PHASE1
200 participants
INTERVENTIONAL
2010-01-31
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Use of DHEA in Women With Premature Ovarian Failure
NCT01129947
Use of Dehydroepiandrosterone (DHEA) in Women With Normal and Poor Ovarian Reserve Undergoing IVF
NCT01915186
Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF
NCT02099916
Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve
NCT02268032
Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility
NCT00650754
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dehydroepiandrosterone
infertile women with low anti mullerian hormone levels
dehydroepiandrosterone
DHEA supplementation 25 mg tid for 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dehydroepiandrosterone
DHEA supplementation 25 mg tid for 3 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
21 Years
44 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Virginia Center for Reproductive Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fady I. Sharara, M.D
Medical Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fady I Sharara, M.D
Role: PRINCIPAL_INVESTIGATOR
Virginia Center for Reproductive Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Virginia Center for Reproductive Medicine
Reston, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet. 2007 Dec;24(12):629-34. doi: 10.1007/s10815-007-9178-x. Epub 2007 Dec 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VCRM 3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.